Preclinical studies using anti-IL-6 or anti-IL-6 receptor (IL-6R) antibodies in tumor-bearing mice demonstrate attenuation of muscle atrophy, adipose tissue loss, and systemic inflammation (27, 41, 145–147). Here, IL6R is linked to neoplasm.